Mp64-17 the role of the urinary, fecal, and prostatic microbiome in prostate cancer: a systematic review

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II (MP64)1 Apr 2020MP64-17 THE ROLE OF THE URINARY, FECAL, AND PROSTATIC MICROBIOME IN PROSTATE CANCER: A SYSTEMATIC REVIEW Matthew DeMasi*, Emily Barry, Kara Watts, and Ahmed Aboumohamed Matthew DeMasi*Matthew DeMasi* More articles by this author , Emily BarryEmily Barry More articles by this author , Kara WattsKara Watts More articles by this author , and Ahmed AboumohamedAhmed Aboumohamed More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000939.017AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Conclusive evidence is lacking regarding the role of the microbiome in the pathogenesis of prostate cancer and its impact on treatment outcomes. We aimed to conduct a systematic review of current literature to address the relationship of the urinary, fecal, and prostatic microbiome and the risk of prostate cancer. METHODS: PubMed, Embase, and Web of Science were searched to identify studies published in English through July 31, 2019. After duplicates were removed, the remaining articles were further filtered by critical review of the titles and abstracts, and by full paper review if unclear. Final articles included in the analysis examined the gastrointestinal or genitourinary (GI/GU) microbiome in prostate cancer. The literature search was completed by two independent reviewers. RESULTS: Initial literature search yielded 284 studies, and 176 studies remained after removing duplicates. Upon further review, 94 studies met criteria after screening by title, 55 studies remained after screening by abstract, and 14 articles were ultimately included after a full paper review. Two studies were prospectively conducted, and one study reported on the racial/ethnic background of patients. Marked variation and heterogeneity existed in result reporting; some studies reported microbiome profiles associated specifically with prostate cancer, while others detailed the general microbiome population by listing species profiles (Table 1). Most studies utilized 16s rRNA to stratify these different microbiome populations. Most notably, a high prevalence of Bacteroides was consistently reported in the fecal and urinary microbiomes of prostate cancer patients. CONCLUSIONS: The relative similarities between microbiome profiles across studies suggest a possible association between the GI/GU microbiome and prostate cancer. However, definitive associations are not yet conclusive due to limited data. There is a need for large-scale, prospective controlled studies, with inclusion of high-risk populations, to examine the role of various microbiomes in the pathogenesis and treatment of prostate cancer. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e970-e970 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Matthew DeMasi* More articles by this author Emily Barry More articles by this author Kara Watts More articles by this author Ahmed Aboumohamed More articles by this author Expand All Advertisement PDF downloadLoading ...